The data show a clear trend toward integrating liquid biopsy for treatment monitoring, MRD detection, and even considering a "liquid-first" approach in select advanced cases where rapid molecular insights are needed.
← all excerpts
Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India.
1
—
—